A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Peer Review reports

Original Submission
31 Aug 2022	Submitted	Original manuscript
2 Oct 2022	Reviewed	Reviewer Report - Ashish Manne
7 Oct 2022	Reviewed	Reviewer Report
13 Oct 2022	Author responded	Author comments - Ning Li
Resubmission - Version 2
13 Oct 2022	Submitted	Manuscript version 2
14 Oct 2022	Reviewed	Reviewer Report
19 Oct 2022	Reviewed	Reviewer Report - Ashish Manne
2 Nov 2022	Author responded	Author comments - Ning Li
Resubmission - Version 3
2 Nov 2022	Submitted	Manuscript version 3
Publishing
4 Nov 2022	Editorially accepted
8 Dec 2022	Article published	10.1186/s12916-022-02649-x

Back to article page